8 results about "Corneal disease" patented technology

The application discloses a line confocal OCT corneal imaging device and method integrated with a liquid lens automatic focusing, a light source module outputs light, the light passes through a line illumination generation module along an optical axis, enters a first beam splitter to form two light beams, and the two light beams enter a sample arm module to be incident to a cornea to form a reflection and scattering light beam carrying corneal information; and enter a reference arm module, pass through a second reflector to form a reference light beam; the reflection and scattering light beam and the reference light beam return to the first beam splitter along the optical axis to interfere to generate a corneal low-coherence interference signal, and sequentially enter an imaging expansion module and a spectrometer module along the optical axis to image; a computer centrally controls a first detector in the spectrometer module, an electrically-controlled displacement table in the reference arm module and a second detector in a liquid lens module; the liquid lens module is optically coupled to the sample arm module through a dichroic mirror to realize real-time measurement of an axial eye movement. The application provides a safer and more reliable inspection tool for early diagnosis and precise evaluation of corneal diseases.

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

Current treatments for corneal disorders, also called keratopathies, depend on the stage of the keratopathy. For mild keratopathies, supportive treatments such as saline eyedrops may be sufficient to ameliorate symptoms. The present disclosure provides methods of treating corneal disorders with modulators of the WNT signaling pathway. More particularly, provided are treatments for cornea epithelial and / or endothelial injuries, defects, deficiencies, and dystrophies. Further provided are methods of dosing and pharmaceutical compositions for the treatment of corneal disorders.

This invention provides a corneal disease diagnosis system, method, and terminal based on anterior segment photography. The acquired anterior segment photograph is input into a corneal disease diagnosis model based on the fusion of learnable wavelet and Morse topological features to obtain diagnostic results. In the model, a frequency-aware modulation module performs learnable frequency domain decomposition and sub-band modulation on the input image to obtain frequency domain features and reliability scores; a topology-aware module globally models the long-range dependencies of the topological response at different scales and locations of the image to obtain topological embedding features and response scores. A confidence-aware topology and frequency fusion module uses a bidirectional cross-attention mechanism to align, modulate, and perceive consistency across modalities to obtain diagnostic results. This invention introduces Morse theory modeling into the topological structure branch to construct stable corneal morphological representations at multiple scales, and combines this with the Mamba model to efficiently model long-range dependencies; the frequency domain representation branch highlights discriminative frequency components, suppresses interference, and improves the stability of texture features. Furthermore, a fusion mechanism is designed to achieve adaptive correction and complementarity of heterogeneous features, and a reliability voting strategy is introduced to improve the robustness and credibility of the diagnostic results.

The application discloses a PROTAC nanocomposite, a preparation method and application thereof in products for treating ophthalmic diseases, relates to the technical field of biological medicine, and the PROTAC nanocomposite comprises a lipid layer and a PROTAC chimera for targeted degradation of ACSL4 wrapped in the lipid layer; wherein the lipid layer comprises an ionizable cationic lipid, cholesterol, DOPE and DSPE-PEG2000; the mass ratio of the ionizable cationic lipid, cholesterol, DOPE, DSPE-PEG2000 and the PROTAC chimera for targeted degradation of ACSL4 is (1.5-2.5):(0.8-1.2):(0.3-0.7):(1.5-2.5):1, based on the mass of the PROTAC nanocomposite; and the PROTAC nanocomposite can be applied to products for treating ophthalmic diseases, in particular, refractory corneal diseases, such as relieving and treating corneal alkali burn.

This disclosure features clusterin (CLU) as a multifunctional biotherapeutic for promoting ocular nerve regeneration for various ocular conditions. This disclosure features methods of using CLU for treating a subject with an ocular disorder, condition, or disease (e.g., an ocular surface disease, corneal disease or retinal disease). The methods described herein can be used for the treatment of ocular inflammatory conditions involving barrier disruption and nerve loss due to its ability to protect and promote the regeneration of ocular nerves.